Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This an an open-label study to define the safety profile and the maximum tolerated dose and
confirm the clinical effective dose of palifosfamide-tris given intravenously in combination
with etoposide and carboplatin in a wide range of cancers which etoposide and carboplatin are
normally given. Once the maximum dose of palifosfamide-tris is determined,a Phase II study
using the 3 agents combined will begin.